VivoSeq
Neurology

Relapsing-Remitting Multiple Sclerosis

100

Pipeline Programs↗

11

Active Trials↗

36

Companies Involved↗

Relapsing-Remitting Multiple Sclerosis is a moderately active landscape with 100 programs across 36 companies. The most active players are Quince Therapeutics S.p.A., Johnson & Johnson, Bristol-Myers Squibb. 25 therapies are approved with 28 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

19/100

Mech. Concentration

7/100

Completion Rate

75/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Q

Quince Therapeutics S.p.A.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2G

Glaxo Dba Glaxosmithkline

2 programs

Phase 2GSK logo

GSK

1 program

Phase 2B

Beijing InnoCare Pharma Tech Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical10

Ocrelizumab

Roche

Natalizumab

Biogen

Daclizumab

Roche

Ublituximab

TG Therapeutics, Inc.

Modafinil

Nuvo Research GmbH

Phase 15

Methylphenidate Hydrochloride

Takeda

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

BCD-132

Biocad

Helminth Ova

University of Wisconsin, Madison

FMP30 Donor Stool

Jeffrey Gelfand

Phase 232

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Mitoxantrone

EMD Serono

Melatonin

Neurim Pharmaceuticals Ltd.

Belimumab

Glaxo Dba Glaxosmithkline

Domperidone

Johnson & Johnson

Phase 328

Dextromethorphan

Pfizer

Interferon Beta-1a

EMD Serono

Interferon Beta-1b

Bayer

Glatiramer Acetate

Teva

Influenza Virus Vaccine

Sanofi

Approved25

Dimethyl Fumarate

Biogen

Fingolimod

Novartis

Venlafaxine

Wyeth-Lederle Vaccines

Cyclophosphamide

Baxter Healthcare Corporation

Ergocalciferol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

83%

Small molecule

82 of 99 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody1515%Protein / enzyme11%Vaccine11%

Small molecule leads; the ring shows all 99 classified programs, each share of the total. Modality classified for 99% of 108 pipeline programs.

Analysis

Trial Status

100

clinical trials

Completed64 · 64%
Terminated17 · 17%
Recruiting4 · 4%
Withdrawn4 · 4%
Active, not recruiting4 · 4%
Unknown status4 · 4%
Other3 · 3%

Clinical Trials

Trial Activity

100 trials

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Recruiting·CCelltrion·Phase 3·NCT05906992·512 enrolled
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Recruiting·BBiocad·Phase 3·NCT07321093·292 enrolled
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Recruiting·SSetPoint Medical Corporation·N/A·NCT06796504·60 enrolled
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Recruiting·RRennes University Hospital·Phase 3·NCT05758831·386 enrolled
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Active, not recruiting·Biogen logoBiogen·N/A·NCT05925049·400 enrolled
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Active, not recruiting·Roche logoRoche·Phase 3·NCT05123703·188 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Active, not recruiting·Biogen logoBiogen·Phase 3·NCT03958877·152 enrolled
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Active, not recruiting·Roche logoRoche·Phase 2·NCT04075266·23 enrolled
Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis
Not yet recruiting·—·N/A·NCT07029867·152 enrolled
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT06663189·200 enrolled
An Open-label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis
Not yet recruiting·Roche logoRoche·Phase 2·NCT07503340·25 enrolled
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT01006265·464 enrolled
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Completed·—·Phase 2·NCT00616187·41 enrolled
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Completed·EMD Serono logoEMD Serono·Phase 3·NCT00213135·1,326 enrolled
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT01111656·28 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)